Audrey Rostov
Ophthalmology · Bellevue, WANPI 1427057512
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (54.1%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. It is spread thinly across 28 manufacturers, the largest accounting for just 22.6%. Among ophthalmology clinicians in WA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 305 payments — averaging $507.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Carl Zeiss Meditec, Inc.$35K
- Bausch & Lomb, A Division Of Bausch Health US, LLC$31K
- Bausch & Lomb Americas Inc.$23K
- Rxsight Inc$18K
- Lensar, Inc.$18K
- Kala Pharmaceuticals, Inc.$7K
- plus $22K from 22 others
Across 41 payments — averaging $1600.97 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Glaukos Corporation$43K
- Oyster Point Pharma, Inc.$23K
What the payments were for
- Consulting fees$83,75554%
- Speaking & faculty fees$55,05036%
- Travel & lodging$2,1521%
- Food & beverage$13,5319%
- Gifts$1960%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Carl Zeiss Meditec, Inc. | 43 | $35,001 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 50 | $31,456 |
| Bausch & Lomb Americas Inc. | 43 | $22,923 |
| Rxsight Inc | 6 | $18,443 |
| Lensar, Inc. | 16 | $17,621 |
| Kala Pharmaceuticals, Inc. | 13 | $7,482 |
| Carl Zeiss Meditec USA, Inc. | 24 | $5,610 |
| Glaukos Corporation | 9 | $2,986 |
| Johnson & Johnson Surgical Vision, Inc. | 3 | $2,528 |
| Microsurgical Technology, Inc. | 1 | $2,000 |
| Dompe US, Inc. | 10 | $1,856 |
| AbbVie(2 entities) | 15 | $1,820 |
| Thea Pharma Inc. | 3 | $915 |
| Shire North American Group Inc | 2 | $824 |
| Sun Pharmaceutical Industries Inc. | 19 | $760 |
| Tarsus Pharmaceuticals, Inc. | 10 | $749 |
| Novartis | 11 | $454 |
| Alcon | 9 | $420 |
| Oyster Point Pharma, Inc. | 3 | $318 |
| Eyevance Pharmaceuticals LLC | 4 | $159 |
| Ocular Therapeutix, Inc. | 1 | $77 |
| Quidel Corporation | 1 | $76 |
| Biotissue Holdings Inc. | 3 | $71 |
| Sight Sciences, Inc. | 1 | $42 |
| Carl Zeiss Meditec AG | 2 | $39 |
| Amgen | 1 | $25 |
| Aerie Pharmaceuticals, Inc. | 1 | $15 |
| Iridex Corporation | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VisuMax$33,971
- LIGHT ADJUSTABLE LENS (LAL) AND LIGHT DELIVERY DEVICE (LDD)$18,346
- MIEBO$17,901
- LENSAR LASER SYSTEM$17,600
- XIIDRA$16,451
- LOTEMAX SM$14,842
- VERACITY SURGICAL$11,785
- STELLARIS$10,879
- IOLMaster 700$9,931
- CALLISTO eye$5,240
- LIPIFLOW SYSTEM ACTIVATOR (DISPOSABLE)$5,000
- MEL 90$4,551
- QUATERA 700$3,806
- CIRRUS HD-OCT$3,676
- LACRISERT$3,660
- EYSUVIS$3,200
- INVELTYS$3,123
- PROLENSA$3,106
- ARTEVO 800$3,050
- Cataract Suite$2,750
How this compares
$154,683 in reported general payments places this provider in the 95th percentile of 428 ophthalmology providers in Washington.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Cyclosporine | 13 | $3,570 |
| Lotemax SmLoteprednol Etabonate | 11 | $2,773 |
| Prednisolone Acetate | 44 | $2,031 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bausch & Lomb, A Division Of Bausch Health US, LLCLotemax Sm | $31,456 | $2,77311 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 428 ophthalmology providers in Washington.
Other ophthalmology in Bellevue
- David SapersteinBellevue$54K
- Howard BarnebeyBellevue$53K
- Mary CodayBellevue$10K
- Stephanie HsuBellevue$6K
- Laura PerimanSeattle$1.7M
- Sheldon CowenSeattle$560K
- Todd SchneidermanSilverdale$200K
- Jennifer ChaoSeattle$188K
- Mark KontosSpokane Valley$175K
- John SamplesOlympia$115K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.